Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Zypitamag Patent Expiration

Zypitamag is a drug owned by Medicure International Inc. It is protected by 1 US drug patent filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 19, 2031. Details of Zypitamag's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US8829186 Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof
Jan, 2031

(6 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Zypitamag is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zypitamag's family patents as well as insights into ongoing legal events on those patents.

Zypitamag's Family Patents

Zypitamag has patent protection in a total of 3 countries. It's US patent count contributes only to 50.0% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Zypitamag.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Zypitamag's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 19, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zypitamag Generics:

There are no approved generic versions for Zypitamag as of now.





About Zypitamag

Zypitamag is a drug owned by Medicure International Inc. Zypitamag uses Pitavastatin Magnesium as an active ingredient. Zypitamag was launched by Medicure in 2017.

Approval Date:

Zypitamag was approved by FDA for market use on 14 July, 2017.

Active Ingredient:

Zypitamag uses Pitavastatin Magnesium as the active ingredient. Check out other Drugs and Companies using Pitavastatin Magnesium ingredient

Dosage:

Zypitamag is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 4MG BASE TABLET Prescription ORAL
EQ 1MG BASE TABLET Discontinued ORAL
EQ 2MG BASE TABLET Prescription ORAL